Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma

Abstract

Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT. Preliminary results suggested a positive impact on survival. A phase III study to definitively test this neoadjuvant-concurrent strategy is warranted.

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy with or without Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Meta-analysis of 1,096 Patients from 11 Randomized Controlled Trials

“…Of the last 14 articles, two trials were almost the same in design and data with different authors (Sun et al, 2009;Zhong et al, 2011), and then zhong et al's trial (Zhong et al, 2011) was discarded. Another two trials (Chan et al, 2005;Hui et al, 2009) were the same in design and data with almost the same authors but different numbers of patients, and in order to avoid data reduplication, then Chan et al's trial (Chan et al, 2005) was discarded. Two trials (Fountzilas et al, 2009;Fountzilas et al, 2012) were from the same study but were reported in different follow-ups.…”

“…All satisfied the criteria of complete outcome data (He et al, 2009;Hui et al, 2009;Ma et al, 2009;Sun et al, 2009;He et al, 2011;Ruste et al, 2011;Xu et al, 2011;Chen et al, 2012;Cui et al, 2012;Fountzilas et al, 2012;Huang et al, 2012), two studies didn't satisfied the item of selective reports He et al, 2011). There were no studies reporting allocation concealment, binding of participants and personnel, and binding of outcome assessment.…”

“…Of eleven studies, six studies reported adequate reliability determined random sequence generation (He et al, 2009;Hui et al, 2009;Ruste et al, 2011;Chen et al, 2012;Fountzilas et al, 2012;Huang et al, 2012). All satisfied the criteria of complete outcome data (He et al, 2009;Hui et al, 2009;Ma et al, 2009;Sun et al, 2009;He et al, 2011;Ruste et al, 2011;Xu et al, 2011;Chen et al, 2012;Cui et al, 2012;Fountzilas et al, 2012;Huang et al, 2012), two studies didn't satisfied the item of selective reports He et al, 2011).…”

“…However, significant heterogeneity existed among trials (P = 0.06, I 2 = 59%). According to the results of sensitivity analysis, one trial (Hui et al, 2009) was excluded, there was no significant difference in 3 years OS between the two groups (RR 0.99 95%CI 0.72-1.36, heterogeneity P = 0.49, I 2 = 0.0%).…”

“…PFS: Three eligible studies (Hui et al, 2009;Ruste et al, 2011;Fountzilas et al, 2012) had the data of 3 years PFS which included 120 patients in the IC+CCRT group and 116 patients in the CCRT+/-AC group. There was significant difference in favor of the IC+CCRT group (RR 0.69 95%CI 0.48-0.97).…”